Results 61 to 70 of about 76,053 (241)

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa, Itaru Yasufuku, Hironori Ishigami, Masahiro Yura, Takanobu Yamada, Shigeaki Baba, Takeshi Kubota, Erina Nagai, Seito Fujibayashi, Mitsumasa Yoshida, Takahiro Kinoshita, Nobuhisa Matsuhashi, Masanori Terashima   +12 more
wiley   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma, Ryo Ashida, Takeshi Kawakami, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Yoshiyasu Kato, Kentaro Yamazaki, Katsuhiko Uesaka, Teiichi Sugiura   +9 more
wiley   +1 more source

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]

, 2017
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David, Gatalica, Zoran, Heestand, Gregory M, Kurzrock, Razelle, Schwaederle, Maria   +4 more
core   +1 more source

Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown.
Takayoshi Sasaki, Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Yuzo Harada, Soichiro Ishihara   +9 more
wiley   +1 more source

Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2013
BackgroundCapecitabine has proven effective as a chemotherapy for metastatic breast cancer. Though several Phase II/III studies of capecitabine as neoadjuvant chemotherapy have been conducted, the results still remain inconsistent.
Qiuyun Li, Yi Jiang, Wei Wei, Huawei Yang, Jianlun Liu   +4 more
doaj   +1 more source

Targeted drug delivery of capecitabine to mice xenograft gastric cancer by PAMAM dendrimer nanocarrier [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Aims: This study used an animal xenograft model of gastric cancer induction to investigate the therapeutic effects of capecitabine polyamidoamine (PAMAM) dendrimer complex against cancer and its potential side effects.
Sharareh Jafari, Fatemeh Nabavizadeh, Jalal Vahedian, Mehdi Ardestani, Hedayat Samandari, Ali Mehrjerdi   +5 more
doaj   +1 more source

Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society [PDF]

, 2009
Background: No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices.
Boeck, Stefan, Bruns, Christiane J., Heinemann, Volker, Jauch, Karl-Walter, Sargent, Mirja, Schäfer, Claus, Seufferlein, Thomas   +6 more
core   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

npj Breast Cancer, 2017
Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast
Jo Anne Zujewski, Lawrence Rubinstein
doaj   +1 more source